GIM-122

N/A

Report date: 2023/08/17 09:56:36

First In Class

Base Information

Drug NameGIM-122

Drug Alias NameGIM-122

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionT lymphocytes stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects

TargetsUpdating

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesGeorgiamune Inc

China Registration ClassN/A

Active CompaniesGeorgiamune Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsNeoplasms

ATC CodeN/A